Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects

Journal of Cardiac Failure

Volumn 7, Issue 3, 2001, Pages 265-268

  Latif, Farhana ^a   Tandon, Suman ^a   Obeleniene, Rimvida ^a   Hankins, Shelley R ^a   Berlowitz, Michael S ^a   Ennezat, Pierre Vladimir ^a   Le Jemtel, Thierry H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin II; Chronic heart failure; Receptor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; PLACEBO; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; FEMALE; HEART FAILURE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT PLANNING;

EID: 0034827191     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2001.26242     Document Type: Article

References (15)

1. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
2. Angiotensin receptors and their antagonists
3. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study ELITE II
4. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
5. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to asses the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
6. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
7. Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
8. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
9. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects
10. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
11. Angiotensin II receptor blockade in normotensive subjects. A direct comparison of three AT1 receptor antagonists
12. Angiotensin II receptor antagonists
13. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
14. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure
15. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection